JACC:经导管二尖瓣修复的机构经验和临床结局

2019-07-25 xiangting MedSci原创

对于使用MitraClip的经导管二尖瓣修复,机构经验增加与手术成功率、手术时间和手术并发症的改善相关。

这项研究目的是探讨经导管二尖瓣修复的机构经验与手术结局之间的关联。

用于治疗二尖瓣返流(MR)的经导管二尖瓣修复是一种复杂的手术,需要使用超声心动图的引导对左心房、左心室和二尖瓣装置进行导航。

来自胸外科医师协会/美国心脏病学会TVT(经导管瓣膜治疗)登记的MitraClip手术根据位点特异性病例序列(1-18、19-51和52-482)分层为三分位。分析了包括手术成功率、手术时间和手术并发症的院内结局。为了评估手术的学习曲线,使用病例序列号作为连续性变量建立了广义线性混合模型。

分析了2013年11月至2017年9月在275个地点进行的MitraClip手术(n=12,334)。不同病例经验三分位间的最佳手术成功(残余MR≤1+,无死亡或不需要心脏手术)逐渐升高(62.0%、65.5%和72.5%;p<0.001),而手术时间和手术并发症减少。不同经验三分位间的可接受手术成功(残余MR≤2+,无死亡或不需要心脏手术)也有升高,但差异较小(91.2%、91.2%和92.9%; p=0.006)。学习曲线分析中,约50个病例后,手术时间、手术成功率和手术并发症出现明显视觉拐点,并且持续改善至200个病例。

对于使用MitraClip的经导管二尖瓣修复,机构经验增加与手术成功率、手术时间和手术并发症的改善相关。在考虑达到最佳MR减少的目标时,机构经验的影响更大。
.
原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1735688, encodeId=40e51e35688d6, content=<a href='/topic/show?id=be5123894c6' target=_blank style='color:#2F92EE;'>#二尖瓣修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23894, encryptionId=be5123894c6, topicName=二尖瓣修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2033947151, createdName=fengyi823, createdTime=Thu Mar 19 21:02:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843196, encodeId=cf691843196b9, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Dec 03 19:02:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854460, encodeId=e2ec1854460cb, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Nov 18 10:02:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326285, encodeId=1922132628542, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463255, encodeId=edaa14632554d, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510234, encodeId=dbac1510234e7, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1735688, encodeId=40e51e35688d6, content=<a href='/topic/show?id=be5123894c6' target=_blank style='color:#2F92EE;'>#二尖瓣修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23894, encryptionId=be5123894c6, topicName=二尖瓣修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2033947151, createdName=fengyi823, createdTime=Thu Mar 19 21:02:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843196, encodeId=cf691843196b9, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Dec 03 19:02:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854460, encodeId=e2ec1854460cb, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Nov 18 10:02:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326285, encodeId=1922132628542, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463255, encodeId=edaa14632554d, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510234, encodeId=dbac1510234e7, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1735688, encodeId=40e51e35688d6, content=<a href='/topic/show?id=be5123894c6' target=_blank style='color:#2F92EE;'>#二尖瓣修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23894, encryptionId=be5123894c6, topicName=二尖瓣修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2033947151, createdName=fengyi823, createdTime=Thu Mar 19 21:02:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843196, encodeId=cf691843196b9, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Dec 03 19:02:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854460, encodeId=e2ec1854460cb, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Nov 18 10:02:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326285, encodeId=1922132628542, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463255, encodeId=edaa14632554d, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510234, encodeId=dbac1510234e7, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
    2019-11-18 hbwxf
  4. [GetPortalCommentsPageByObjectIdResponse(id=1735688, encodeId=40e51e35688d6, content=<a href='/topic/show?id=be5123894c6' target=_blank style='color:#2F92EE;'>#二尖瓣修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23894, encryptionId=be5123894c6, topicName=二尖瓣修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2033947151, createdName=fengyi823, createdTime=Thu Mar 19 21:02:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843196, encodeId=cf691843196b9, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Dec 03 19:02:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854460, encodeId=e2ec1854460cb, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Nov 18 10:02:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326285, encodeId=1922132628542, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463255, encodeId=edaa14632554d, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510234, encodeId=dbac1510234e7, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1735688, encodeId=40e51e35688d6, content=<a href='/topic/show?id=be5123894c6' target=_blank style='color:#2F92EE;'>#二尖瓣修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23894, encryptionId=be5123894c6, topicName=二尖瓣修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2033947151, createdName=fengyi823, createdTime=Thu Mar 19 21:02:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843196, encodeId=cf691843196b9, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Dec 03 19:02:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854460, encodeId=e2ec1854460cb, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Nov 18 10:02:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326285, encodeId=1922132628542, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463255, encodeId=edaa14632554d, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510234, encodeId=dbac1510234e7, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
    2019-07-27 wwzzly
  6. [GetPortalCommentsPageByObjectIdResponse(id=1735688, encodeId=40e51e35688d6, content=<a href='/topic/show?id=be5123894c6' target=_blank style='color:#2F92EE;'>#二尖瓣修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23894, encryptionId=be5123894c6, topicName=二尖瓣修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2033947151, createdName=fengyi823, createdTime=Thu Mar 19 21:02:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843196, encodeId=cf691843196b9, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Dec 03 19:02:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854460, encodeId=e2ec1854460cb, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Nov 18 10:02:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326285, encodeId=1922132628542, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463255, encodeId=edaa14632554d, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510234, encodeId=dbac1510234e7, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Sat Jul 27 02:02:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
    2019-07-27 lsj631

相关资讯

JAMA Cardiol:经导管二尖瓣修复与30天和1年生活质量结局的关联

在这个接受缘对缘TMVR的全国性美国患者队列中,患者术前健康状况受损,并在30天内改善,有可用数据的存活患者在1年内健康状态保持稳定。

JAHA:经导管二尖瓣修复后左心房功能的预后影响

目前的分析表明在接受MitraClip植入的患者中,LA功能的变化与包括残余二尖瓣反流、跨瓣梯度升高和左心室功能在内的重要指标相关。

JACC:三维缩流面积量化MitraClip术后残余二尖瓣返流的诊断价值

在E-EC经导管二尖瓣修复后,使用3D彩色多普勒经食管超声心动图测量VCA是可行的,并能可靠地量化MR。

Eur Heart J:经导管瓣膜治疗患者的虚弱性和相关结局

这项研究使用基于ICD-10索赔的医院虚弱风险评分,成功识别出美国老年人群中接受经导管瓣膜治疗后长短期死亡风险升高的个体。

Heart:手术高危患者经导管减少明显二尖瓣返流的5年预后

EVEREST II HRS证实了MitraClip在手术高危患者中5年的长期安全性和疗效。

Circulation:MitraClip®用于功能性二尖瓣返流的一年预后

在继发性MR患者中使用MitraClip进行经导管MV修复与可接受的安全性、MR严重程度的降低、症状改善和积极的心室重构相关。